Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma
- PMID: 28400549
- PMCID: PMC5398423
- DOI: 10.12659/msm.900977
Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma
Abstract
BACKGROUND Prostate carcinoma (PCa) is often not diagnosed until advanced disease with bone metastasis. Predictive factors for bone metastasis are required to improve patient outcomes. The study aimed to analyze the factors associated with bone metastases in newly diagnosed patients with PCa. MATERIAL AND METHODS This was a retrospective study of 80 patients newly diagnosed with PCa by pathological examination between January 2012 and December 2014. Bone metastases were diagnosed by positron emission computed tomography. Clinical data, serological laboratory results, and pathological examination results were collected. RESULTS Among the 80 patients, 45 (56%) had bone metastases. Age, serum alkaline phosphatase, prostate-specific antigen (PSA), erythrocyte sedimentation rate, PCa tissue Gleason score, androgen receptor (AR) expression, and Ki-67 expression were higher in patients with bone metastasis compared with those without (all P<0.05). Multivariate logistic regression showed that PSA (OR: 1.005; 95%CI: 1.001-1.010; P=0.016), Gleason score (OR: 4.095; 95%CI: 1.592-10.529; P=0.003), and AR expression (OR: 14.023; 95%CI: 3.531-55.6981; P=0.005) were independently associated with bone metastases. Cut-off values for PSA, Gleason score, and AR expression were 67.1 ng/ml (sensitivity: 55.6%; specificity: 97.1%), 7.5 (sensitivity: 75.6%; specificity: 82.9%), and 2.5 (sensitivity: 84.0%; specificity: 91.4%), respectively. CONCLUSIONS PSA, Gleason score, and AR expression in PCa tissues were independently associated with PCa bone metastases. These results could help identifying patients with PCa at high risk of bone metastases.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures


Similar articles
-
[Predictive factors for bone metastases of prostate cancer].Nan Fang Yi Ke Da Xue Xue Bao. 2016 Feb;36(2):205-9. Nan Fang Yi Ke Da Xue Xue Bao. 2016. PMID: 26922017 Chinese.
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.Asian Pac J Cancer Prev. 2015;16(13):5261-4. doi: 10.7314/apjcp.2015.16.13.5261. Asian Pac J Cancer Prev. 2015. PMID: 26225663
-
Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.Front Endocrinol (Lausanne). 2024 Feb 7;15:1338420. doi: 10.3389/fendo.2024.1338420. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38384968 Free PMC article. Review.
-
Predicting the risk of bone metastasis in prostate cancer.Cancer Treat Rev. 2014 Feb;40(1):3-11. doi: 10.1016/j.ctrv.2013.07.001. Epub 2013 Jul 26. Cancer Treat Rev. 2014. PMID: 23896177 Review.
Cited by
-
The miRNAs 203a/210-3p/5001-5p regulate the androgen/androgen receptor/YAP-induced migration in prostate cancer cells.Cancer Med. 2024 Aug;13(16):e70106. doi: 10.1002/cam4.70106. Cancer Med. 2024. PMID: 39149855 Free PMC article.
-
Machine learning discrimination of Gleason scores below GG3 and above GG4 for HSPC patients diagnosis.Sci Rep. 2024 Oct 27;14(1):25641. doi: 10.1038/s41598-024-77033-1. Sci Rep. 2024. PMID: 39465343 Free PMC article.
-
Establishing a prediction model for prostate cancer bone metastasis.Int J Biol Sci. 2019 Jan 1;15(1):208-220. doi: 10.7150/ijbs.27537. eCollection 2019. Int J Biol Sci. 2019. PMID: 30662360 Free PMC article.
-
Isolated Testicular Metastasis from Prostate Cancer.Am J Case Rep. 2017 Aug 14;18:887-889. doi: 10.12659/ajcr.904521. Am J Case Rep. 2017. PMID: 28804118 Free PMC article.
-
JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4.Theranostics. 2025 Jan 1;15(4):1320-1337. doi: 10.7150/thno.104135. eCollection 2025. Theranostics. 2025. PMID: 39816691 Free PMC article.
References
-
- Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer Chemother Pharmacol. 2013;71:1629–34. - PubMed
-
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer. Version 2.2014. Fort Washington: National Comprehensive Cancer Network; 2014.
-
- Graham J, Kirkbride P, Cann K, et al. Prostate cancer: Summary of updated NICE guidance. BMJ. 2014;348:f7524. - PubMed
-
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014;64:9–29. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous